Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]
